These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30370429)

  • 1. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
    Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications.
    Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
    Neurotox Res; 2017 Nov; 32(4):639-648. PubMed ID: 28733707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of three angiotensin-converting enzyme inhibitors on kynurenic acid production in rat kidney in vitro.
    Zakrocka I; Kocki T; Turski WA
    Pharmacol Rep; 2017 Jun; 69(3):536-541. PubMed ID: 28364692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors modulate kynurenic acid production in rat brain cortex in vitro.
    Zakrocka I; Turski WA; Kocki T
    Eur J Pharmacol; 2016 Oct; 789():308-312. PubMed ID: 27423316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action.
    Chmiel-Perzyńska I; Perzyński A; Olajossy B; Gil-Kulik P; Kocki J; Urbańska EM
    J Diabetes Res; 2019; 2019():4957879. PubMed ID: 31737685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual effect of DL-homocysteine and S-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid.
    Luchowska E; Luchowski P; Paczek R; Ziembowicz A; Kocki T; Turski WA; Wielosz M; Lazarewicz J; Urbanska EM
    J Neurosci Res; 2005 Feb; 79(3):375-82. PubMed ID: 15605380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-Cycloserine lowers kynurenic acid formation--new mechanism of action.
    Baran H; Kepplinger B
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):639-44. PubMed ID: 24189377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex.
    Bortz DM; Wu HQ; Schwarcz R; Bruno JP
    Neuropharmacology; 2017 Jul; 121():69-78. PubMed ID: 28419874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro.
    Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
    Neurotox Res; 2019 Jan; 35(1):244-254. PubMed ID: 30178287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.
    Mason RP; Jacob RF; Kubant R; Jacoby A; Louka F; Corbalan JJ; Malinski T
    Br J Clin Pharmacol; 2012 Jul; 74(1):141-6. PubMed ID: 22283728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
    Harada N; Shimozawa N; Okajima K
    Transl Res; 2009 Sep; 154(3):142-52. PubMed ID: 19665690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
    Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
    J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
    Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
    J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
    Hattori N; Yamada A; Nakatsuji S; Matsuda T; Nishiyama N; Shimatsu A
    J Mol Endocrinol; 2022 May; 69(1):259-268. PubMed ID: 35354667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.
    Kamiyama E; Yoshigae Y; Kasuya A; Takei M; Kurihara A; Ikeda T
    Drug Metab Pharmacokinet; 2007 Aug; 22(4):267-75. PubMed ID: 17827781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrolysin lowers kynurenic acid formation--an in vitro study.
    Baran H; Kepplinger B
    Eur Neuropsychopharmacol; 2009 Mar; 19(3):161-8. PubMed ID: 19008081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.